background genetic polymorphism determines downregulation desensitization objectives aim present study investigate effects genetic polymorphism ex vivo lymphocytes vivo bronchoprotection function asthmatic patients having washed previous exposure methods patients stable asthma evaluated post hoc analysis genotype performed end study having withheld treatment beta2agonists NUMBER h beta2agonists NUMBER h measurements lymphocyte binding density binding affinity basal cyclic adenosine monophosphate camp maximal camp response isoproterenol emax addition NUMBER patients methacholine responsive pd20 NUMBER microg acute protective effect formoterol single dose NUMBER h evaluated comparisons according homozygous heterozygous het polymorphisms codon NUMBER codon NUMBER results significant differences age fev1 percent predicted inhaled corticosteroid dose comparing mean values polymorphisms codon NUMBER significant differences polymorphisms measured lymphocyte parameters apart basal camp mean values emax isoproterenol cells follows NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER polylorphism significant effect formoterol protection doubling dose shift methacholine pd20 geometric mean NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER conclusions results genetic polymorphism codon NUMBER NUMBER does influence stimulated coupling lymphocyte similarly did influence degree functional antagonism exhibited formoterol single dose used demand affords equal protection bronchoprotection regardless genetic polymorphism agonist induced beta2 adrenoceptors beta2 adrenoceptors beta2 agonist mild moderate long acting short acting beta2 adrenoceptors NUMBER microg codon NUMBER beta2 adrenoceptor glu NUMBER het NUMBER gly NUMBER arg NUMBER het NUMBER glu NUMBER gln NUMBER het NUMBER gly NUMBER arg NUMBER het NUMBER glu NUMBER gln NUMBER het NUMBER beta2 adrenoceptors beta2 agonist pmol NUMBER